Developing kinase inhibitors for malaria: an opportunity or liability?

Abstract

Highly druggable and essential to almost all aspects of cellular life, the protein and phosphoinositide kinase gene families offer a wealth of potential targets for pharmacological modulation for both noncommunicable and infectious diseases. Despite the success of kinase inhibitors in oncology and other disease indications, targeting kinases comes with significant challenges. Key hurdles for kinase drug discovery include selectivity and acquired resistance. The phosphatidylinositol 4-kinase beta inhibitor MMV390048 showed good efficacy in Phase 2a clinical trials, demonstrating the potential of kinase inhibitors for malaria treatment. Here we argue that the potential benefits of Plasmodium kinase inhibitors outweigh the risks, and we highlight the opportunity for designed polypharmacology to reduce the risk of resistance.

• Authors: Koketso S P Mogwera, Kelly Chibale, Lauren B Arendse
• Journal: Trends in parasitology (Trends Parasitol) Vol. 39 Issue 9 Pg. 720-731 (09 2023) ISSN: 1471-5007 [Electronic] England
• PMID: 37385921 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2023 Elsevier Ltd. All rights reserved.

Topics

• Humans
• Malaria (drug therapy)
• Plasmodium (genetics)
• Drug Discovery